Posted: 12 February 2024
Ichor Life Sciences has established operations in Australia, Ireland, and the UK by partnering with local contractors.
The move saw US clinical research organization (CRO) Ichor establish collaborative service offerings with “concierge and boutique” CROs. The aim – according to Lisa Sonneborn, president of Ichor Clinical – is to provide various trial services in the new territories.
“Our mission is to act as a global catalyst, offering personalized global clinical trial services, strategy, and regulatory guidance to life sciences companies of all sizes, including small and medium-sized companies that require a superior level of service.”
The firm will provide trial design and start-up, clinical trial site selection, recruitment planning and strategy, monitoring, data management and statistics, regulatory support, and trial close out.
Down under studies on top
Tina Soulis, founder and director of Ichor’s Australian partner Alithia Life Sciences, cited early clinical trials as a key target market for the firms.
“CROs that grasp the financial and operational benefits of early-stage clinical data in strategically selected countries can provide a distinct financial benefit to their clients, while also allowing for a seamless transition from early phase trials in Australia to later phase trials in the US.”
The growing importance of the Australian early phase drug market was recently detailed in a report by Frost and Sullivan, which cost advantages – early phase trials in the country are 28% cheaper than those in the US – as a major advantage.
Study consistency
Nicola Wall, founder and CEO of Ichor’s new partner in the UK and Ireland, Afortiori Development, cited consistency as a major focus for the collaboration.
“Our international strategy ensures bespoke, high-quality services for clinical trials, transcending geographical boundaries and navigating local regulatory and clinical landscapes. We are dedicated to maintaining consistently high standards globally, contributing effectively to the forefront of medical research advancements.”
The deals follow just a few months after Ichor Clinical launched and are in keeping with the growth strategy the firm outlined at the time.
